Pay in 4 interest-free payments of $7.25 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Novo Nordisk's STEP trials demonstrated that semaglutide produces 15% to 22% average body weight loss over 68 weeksroughly three times more than placebo
The 'counterion' used during peptide synthesis can significantly impact your research data
Based on the pharmacokinetic results, oral semaglutide co-formulated with a fixed amount of 300 mg SNAC was chosen for further clinical development
Clinical trials demonstrate substantial weight reduction with these medications: semaglutide typically produces approximately 15% weight loss in non-diabetic patients, while tirzepatide has shown up to 22% weight loss in clinical trials
Contacts for further information 2025 Novo Nordisk All rights reserved
This purity is verified through multiple testing methods so you can trust your results
